Furthermore, our results also hint that the less specific SGLT2-inhibitor remogliflozin [48], versus the commonly used empagliflozin, could be a better gliflozin to be repurposed to treat neutropenia in G6PC3-deficient and GSD1b patients. This evidence concerns the gene SLC37A4 and neutropenia.